GSK opens state-of-the-art global vaccine centre

pharmafile | December 15, 2016 | News story | Manufacturing and Production, Medical Communications  

GlaxoSmithKline has opened its new global vaccines R&D centre in Rockville, Maryland, to add to its two existing facilities in Rixensart, Belgium, and Seina, Italy. The site is well-located as it is close to the National Institutes of Health and PATH. GSK will continue to invest in the site to the tune of $50 million over the course of the next two years to outfit the site with scientific research technology and equipment.

The new site will host 450 researches and support staff, with up to 200 new positions being created as part of the process. The facility will be responsible for developing a total of 12 vaccine programs. The expansion plays into GSK’s current shift towards bolstering its vaccine business, which was boosted by GSK’s asset swap with Novartis last year that saw them take on board its global human vaccines business for $7.1 billion.

Luc Debruyne, president of GSK Vaccines, said: “We are delighted to be opening our new facility in Rockville, GSK’s first fully dedicated vaccines R&D centre located in the US. Our investment here signifies our commitment to discovering and developing new vaccines across a range of pressing public health priorities, including those important here in the US.  It places GSK at the heart of a dynamic and cutting edge bioscience hub in Washington, D.C.  We look forward to fruitful partnerships and collaborations in this community to advance the science of vaccines, and help improve health of millions of people around the world.”

The facility was purchased back in 2012 from Human Genome Sciences. GSK has been preparing the site from 2015 to be ready for its grand opening. The facility will be officially opened by CEO Andrew Witty, alongside 150 guests.

Ben Hargreaves

Related Content

No items found

Latest content